

Solana Trichomonas ASSAY



Stop compromising. Start treating.

Traditional methods for diagnosing Trichomonas require tradeoffs between cost and accuracy. Wet mount may be rapid and inexpensive, but it lacks in sensitivity (51% to 65%).1 Similarly, rapid antigen tests are fast and easy, but are not as sensitive as their molecular counterparts.² The CDC recommends testing for Trichomonas using highly sensitive Nucleic Acid Amplification Tests, like Solana, to avoid underdiagnosing and undertreating the disease.

Prompt initiation of patient management and antimicrobial therapy

- Results in just 30 minutes means you can help your patients get accurate, same-day treatment
- High volume throughput keeps pace with your busy laboratory

True, Molecular Accuracy

- Confidence in your diagnosis
- More sensitive than wet mount, rapids, and culture

Ease and Affordability

- Clinician collected vaginal swab and female urine samples
- Objective results
- Simple procedure
- Competitive pricing and flexible instrument placement options


The Accurate. Sustainable. Molecular Trichomonas Solution.

- 1. http://www.cdc.gov/std/tg2015/trichomoniasis.htm
- 2. Garber, GE. The laboratory diagnosis of trichomonas vaginalis. The Canadian Journal of Infectious Diseases and Medical Microbiology. 2015;16(1):35-38





Procedure



Clinical Performance

Performance Characteristics of the Solana Trichomonas Assay with Clinician Collected Vaginal Swabs by Symptom Status compared to the Composite Reference Method Wet Mount and Culture

Site Number	Symptom Status	N	TP	FP	TN	FN	Prev %	Sensitivity % (95% CI)	Specificity % (95% CI)
Combined	Asymptomatic	501	50	5	446	0	10.0	100 (92.9 to 100)	98.9 (97.4 to 99.5)
	Symptomatic	542	69	7	465	1	12.9	98.6 (92.3 to 99.7)	98.5 (97.0 to 99.3)
	All	1043	119	12*	911	1*	11.5	99.2 (95.4 to 99.9)	98.7 (97.7 to 99.3)

^{*}Of the one thousand forty-three (1043) specimens evaluated a total of thirteen (13) specimens were discordant. Of the twelve (12) discordant (Solana Positive/Composite Reference Method Negative) specimens, four (4) were positive by an FDA-cleared Trichomonas vaginalis molecular assay. The one (1) discordant (Negative Solana/Composite Reference Method Positive) specimen, it was negative by an FDA-cleared Trichomonas vaginalis molecular assay.

Performance Characteristics of the Solana Trichomonas Assay with Female Urine Specimens by Symptom Status compared to the Composite Reference Method

Site Number	Symptom Status	N	TP	FP	TN	FN	Prev %	Sensitivity % (95% CI)	Specificity % (95% CI)
Combined	Asymptomatic	501	49	7	444	1	10.0	98.0 (89.5 to 99.6)	98.4 (96.8 to 99.2)
	Symptomatic	543	65	10	463	5	12.9	92.9 (84.3 to 96.9)	97.9 (96.2 to 98.8)
	All	1044	114	17	907	6	11.5	95.0 (89.5 to 97.7)	98.2 (97.1 to 98.8)



Solana Trichomonas Assay – Swab – 48 Test Kit: Cat. #23043102

Solana Trichomonas Assay - Urine - 48 Test Kit: Cat. #23043103

Quidel Molecular Trichomonas Control Set – 80-Reaction Kit: Cat. #23043135

Solana Trichomonas Startup Kit – Swab: Cat. #23043105 Solana Trichomonas Startup Kit - Urine: Cat. #23043104

© 2015 Thermo Fisher Scientific Inc. All rights reserved.

Trademarks used are owned as indicated at www.fishersci.com/trademarks.

In the United States:

For customer service, call 1-800-640-0640 To fax an order, use 1-800-290-0290 To order online: www.fisherhealthcare.com



SSM304203EN00 (03/17)